NIAID Preclinical Models of Infectious Diseases 2017-2024

The National Institute of Allergy and Infectious Diseases (NIAID) Preclinical Models of Infectious Diseases 2017-2024 Indefinite Delivery/Indefinite Quantity (IDIQ) contract vehicle is designed to support advanced research into infectious disease modeling and medical countermeasure development. The contract enables NIAID to rapidly procure preclinical research services across a wide range of infectious disease contexts, including the development of animal and non-animal models for studying disease mechanisms, screening potential therapeutics, and evaluating vaccines. The vehicle supports research on various pathogens, including viral, bacterial, fungal, and parasitic infections, with a focus on emerging infectious diseases, pandemic preparedness, and antimicrobial resistance.

Task orders under this IDIQ consistently range from approximately $300,000 to $7 million, with performance periods typically spanning 18 to 36 months. Frequent prime contractors include academic research institutions such as Utah State University, University of Texas Medical Branch at Galveston, University of North Carolina at Chapel Hill, and Pharmacology Discovery Services Taiwan. Most task orders are awarded on a cost-no-fee or firm fixed-price basis, with no specific small business set-aside designations. The work is predominantly performed at university research facilities across the United States, with some international locations like Taiwan. Common research focuses include developing small animal models, non-human primate models, and novel testing platforms for infectious diseases such as COVID-19, influenza, tuberculosis, and emerging viral threats, reflecting NIAID's broader mission of advancing medical countermeasures through preclinical research.